Pharma Focus Asia.com News and commentary for the Pharma Focus Asia. http://www.pharmafocusasia.com/ News and commentary for the Pharma Focus Asia. Tue, 29 Jan 2008 14:42:37 GMTTue, 29 Jan 2008 14:42:37 GMT Ochre Media RSS Generator 2.00en-us Ochre Media Limited http:www.ochre-media.com http://www.pharmafocusasia.com/ http://www.pharmafocusasia.com/images/OchreMedia_logo.gif http://www.pharmafocusasia.com/ Pharma Vertical Talk http://www.pharmafocusasia.com/images/verticaltalk_pharma.jpg
This is formatted XML site feed. It is intended to be viewed in an RSS or Atom Newsreader or syndicated to another site.
http://www.pharmafocusasia.com/news/news_archives.asp?NewsID=445 Wed, 28 Feb 2007 00:00:00 GMT http://www.pharmafocusasia.com/news/news_archives.asp?NewsID=445 Celera and Merck enter agreement for cancer targets Celera announced that it has entered into a two year license agreement with Merck & Co., Inc. Under the agreement, Merck will have access to around ten cancer targets for the development of RNA interference-(RNAi) based therapeutics. These therapeutic targets are over-expressed on the surface of several different tumour cell types and were identified using Celera's proteomics discovery platform. RNAi-based therapeutics help in selectively catalysing the destruction of the RNA transcribed from an individual gene, thereby enabling a novel approach to discovering drugs with the potential to produce highly specific, potent and long-lasting effects. This new agreement combines the strength of our novel proteomics target discovery and validation capability with Merck's expertise in developing RNAi based therapeutics, said Steve Ruben, Vice President, Proteomic Research, Celera. http://www.pharmafocusasia.com/news/news_archives.asp?NewsID=446 Wed, 28 Feb 2007 00:00:00 GMT http://www.pharmafocusasia.com/news/news_archives.asp?NewsID=446 CV Therapeutics and Astellas receive approval for Lexiscan CV Therapeutics, Inc. and Astellas Pharma US, Inc. announced that it has received approval from the US FDA for Lexiscan (regadenoson) injection. It is an A2A adenosine receptor agonist and is administered as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI). The A2A adenosine receptor is the adenosine receptor subtype responsible for coronary vasodilation. Lexicon is delivered as a rapid bolus with no dose adjustment required for body weight. Speaking on this occasion, Louis G. Lange, chairman and chief executive officer, CV Therapeutics, said, Lexiscan represents the second novel chemical entity in cardiovascular medicine that CV Therapeutics has received approval for in just over two years. http://www.pharmafocusasia.com/news/news_archives.asp?NewsID=442 Wed, 28 Feb 2007 00:00:00 GMT http://www.pharmafocusasia.com/news/news_archives.asp?NewsID=442 Ranbaxy and DBT collaborate for NDDR Ranbaxy Laboratories Limited announced that it has entered into a collaborative research agreement with the Department of Biotechnology (DBT), New Delhi, in the area of New Drug Discovery Research (NDDR). The research will be conducted under the aegis of DBTs major initiative in the area of tuberculosis. The major areas identified in the program include development of diagnostics, vaccines and drugs. Under the agreement, Ranbaxy will develop new drugs using inhibitor designs for novel targets, pathways and proteins. Once a molecule is identified, DBT and Ranbaxy will jointly support the clinical development. Speaking on the occasion, Mr Malvinder Mohan Singh, CEO and MD, Ranbaxy Laboratories Limited, said, We are pleased to have this alliance with DBT in the area of NDDR and will work towards building a winning model to develop innovative medicines in the area of tuberculosis.